Stock FATE FATE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
3.54 USD +0.57% Intraday chart for Fate Therapeutics, Inc. -4.32% -5.35%
May. 19 Certain Restricted Stock Units of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
May. 19 Certain Stock Options of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Certain Restricted Stock Units of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Stock Options of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Pre-Funded Warrants of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Class A Convertible Preferred Stock of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Common Stock of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating
MT
Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating
MT
Transcript : Fate Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (FATE) FATE THERAPEUTICS Reports Q1 Revenue $1.9M
MT
Fate Therapeutics: Q1 Earnings Snapshot
AQ
Fate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GL
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
GL
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-The-Shelf FT819 CAR T-Cell Program
CI
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
AQ
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
GL
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
GL
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
GL
Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
CI
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FATE Stock
  4. News Fate Therapeutics, Inc.